Transgene Biotek (BOM:526139) FCF Margin %: 0.00% (As of Mar. 2026)


BOM:526139 Transgene Biotek Ltd BOM:526139
47 GF Score
Price ₹3.11
GF Value ₹6.51
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Transgene Biotek FCF Margin %?

Transgene Biotek BOM:526139 +2.64% 47 FCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates BOM:526139 with a GF Score™ of 47/100 and a GF Value™ of ₹6.51 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 957 Biotechnology companies, Transgene Biotek ranks better than 71.06% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Transgene Biotek's Free Cash Flow for the three months ended in Mar. 2026 was ₹0.00 Mil. Transgene Biotek's Revenue for the three months ended in Mar. 2026 was ₹0.55 Mil. Therefore, Transgene Biotek's FCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Transgene Biotek's current FCF Yield % is -0.05%.

The historical rank and industry rank for Transgene Biotek's FCF Margin % or its related term are showing as below:

BOM:526139' s FCF Margin % Range Over the Past 10 Years
Min: -2544.32   Med: -3.86   Max: 112.8
Current: -5.35

During the past 13 years, the highest FCF Margin % of Transgene Biotek was 112.80%. The lowest was -2544.32%. And the median was -3.86%.

BOM:526139's FCF Margin % is ranked better than
71.06% of 957 companies
in the Biotechnology industry
Industry Median: -84.65 vs BOM:526139: -5.35

Transgene Biotek FCF Margin % Related Terms

Transgene Biotek FCF Margin % Historical Data

* Premium members only.

The historical data trend for Transgene Biotek's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Transgene Biotek FCF Margin % Chart

Transgene Biotek Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 112.80 -2.36 1.96 -193.21 -5.35

Transgene Biotek Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BOM:526139 vs VRTX, REGN, ALNY: FCF Margin % Comparison

For the Biotechnology subindustry, Transgene Biotek's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Transgene Biotek FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Transgene Biotek's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Transgene Biotek's FCF Margin % falls into.


BOM:526139
47GF Score
Transgene Biotek Ltd BOM:526139
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Transgene Biotek FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Transgene Biotek's FCF Margin for the fiscal year that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (A: Mar. 2026 )/Revenue (A: Mar. 2026 )
=-0.113/2.112
=-5.35 %

Transgene Biotek's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=0/0.545
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 0.00% mean?
Transgene Biotek (BOM:526139) has a FCF Margin % of 0.00% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Transgene Biotek and its competitors. According to the industry distribution chart, Transgene Biotek ranks #277 out of 957 companies in the Biotechnology industry, placing it in the top 28.9%.
Is Transgene Biotek's FCF Margin % too high?
Transgene Biotek's current FCF Margin % is 0.00%. Based on the distribution chart, Transgene Biotek ranks #277 out of 957 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Transgene Biotek has a GF Score™ of 47/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Transgene Biotek's FCF Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Transgene Biotek ranks #277 out of 957 companies for FCF Margin %. This puts Transgene Biotek in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Transgene Biotek and its competitors. Transgene Biotek's current FCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Transgene Biotek stock overvalued right now?
Based on GuruFocus' analysis, Transgene Biotek (BOM:526139) is currently considered Possible Value Trap. The stock's GF Value™ is ₹6.51, compared to a current price of ₹3.11 — trading 52.2% below its estimated fair value. The current FCF Margin % is 0.00%. Transgene Biotek's overall GF Score™ is 47/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Transgene Biotek (BOM:526139), the current FCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Transgene Biotek (BOM:526139) Overvalued in 2026?

Based on GuruFocus' analysis, Transgene Biotek stock appears to be undervalued. The current stock price of ₹3.11 is trading 52.2% below its estimated GF Value™ of ₹6.51. GuruFocus considers Transgene Biotek to be Possible Value Trap.

Key valuation signals for BOM:526139:

  • FCF Margin %: 0.00%
  • GF Value™: ₹6.51 vs. price of ₹3.11 (52.2% below fair value)
  • GF Score™: 47/100 with 4 warning signs

No single metric tells the full story. See the BOM:526139 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Transgene Biotek Business Description

Address Anrich Industrial Area, Plot No. 69 and 70, IDA Bollaram, Sangareddy District, Medak, TG, IND, 502325
Transgene Biotek Ltd is an India-based research and development company. It is engaged in the research and development of molecules and technologies for the production of active pharmaceutical ingredients and other pharmaceutical products. The company is operating only in one segment of Bulk Drugs. Its product portfolio includes TrabiDHA, Tracolimus, and Orlistat. It generates revenue from the sale of goods and services.
47GF Score

Get the complete analysis for BOM:526139

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹3.11
Price
₹6.51
GF Value